 |
DAEJEON, South Korea, Nov. 16, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.
The clinical study was conducted in Australiafr...
Land clearing and vegetation management are essential activities across construction, agriculture, forestry, utility maintena...
When a crisis dominates headlines, most business owners focus on survival. Cash flow becomes king. Expansion plans are po...
Australia’s major supermarkets are transforming consumer behaviour through home delivery and click and collect services, bu...
The corporate landscape in Australia has undergone a permanent structural shift over the past few ...
On Saturday 6 June, parkrun events across the state will be a sea of maroon, with communities str...
In an Australian first, an innovative new bladder cancer treatment clinical trial that harnesses t...
Australians thinking about a holiday in the Northern Territory have another reason to start planni...
Australians thinking about a holiday in the Northern Territory have another reason to start planni...
Homesafe Wealth Release says More Australians Are Using Housing Wealth to Fund Ageing at Home As mo...
In an Australian first, an innovative new bladder cancer treatment clinical trial that harnesses t...